中國同輻(01763.HK) 與中國原子能科學研究院簽署戰略合作協議
中國同輻(01763.HK)公布,於今年4月7日與中國原子能科學研究院簽署戰略合作協議。
根據該協議,雙方將本著「優勢互補、互惠互利、協同共贏、共同發展」的原則, 圍繞核醫療、輻照應用等領域,在技術研發、產品研製、成果轉化、平台建設和 產業化發展等方面開展全面合作,合力推進同位素相關重大基礎設施建設,建強關鍵同位素自主供應能力,提升同位素及放射性藥物、放射源研發創新水平,助力核技術應用高質量發展。
集團指,此次戰略合作協議的簽署,標誌著雙方將在更深層次、更廣領域開展更高水平的合作,對於公司未來的科技創新和產業發展具有重要戰略意義。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.